Low dose (d1-5/7) oral etoposide regimen in intensively treated platinum-resistant epithelial ovarian cancer: The İzmir oncology group (IZOG) study
| dc.contributor.author | Taskaynatan, Halil | |
| dc.contributor.author | Kucukzeybek, Yuksel | |
| dc.contributor.author | Yildiz, Yasar | |
| dc.contributor.author | Salman, Tarik | |
| dc.contributor.author | Oflazoglu, Utku | |
| dc.contributor.author | Varol, Umut | |
| dc.contributor.author | Alacacioglu, Ahmet | |
| dc.contributor.author | Saray, Seray | |
| dc.contributor.author | Ozdemir, Ozlem | |
| dc.contributor.author | Tarhan, Mustafa Oktay | |
| dc.date.accessioned | 2022-03-08T10:35:41Z | |
| dc.date.available | 2022-03-08T10:35:41Z | |
| dc.date.issued | 2020 | |
| dc.department | İnönü Üniversitesi | en_US |
| dc.description.abstract | Aim: Oral etoposide dosage is roughly 50-100 mg/m2 on days 1 to 21 every 28 days. However, dosage of 50 mg/day oral etoposide for five days a week is not well published. The present study, aimed to evaluate the efficacy and toxicity profile of low dose oral etoposide regimen (50 mg/day on days 1 to 5 every week) in platinum-resistant epithelial ovarian cancer (EOC).Material and Methods: This study retrospectively evaluates patients with pathologically confirmed platinum-resistant EOC who were unable to tolerate the standard oral etoposide regimen and were on low dose (d1-5/7) oral etoposide regimen in third line or beyond within the period between 2006 and 2014.Results: The overall response rate among 33 EOC patients was 15.1% while clinical benefit rate was 42.4% (stable disease in 27.3% and partial response in 15.1%). Median progression-free survival was 4 months (95% confidence interval [CI], 2.8–5.1 months) and median overall survival was 12 months (95% CI, 8.8–15.1 months). Conclusion: We concluded that low dose oral etoposide (50 mg/day, on days 1 to 5 every week) was effective and well tolerated for platinum-resistant EOC. | en_US |
| dc.identifier.citation | Taskaynatan, H., Kucukzeybek, Y., Yildiz, Y., Salman, T., Oflazoglu, U., Varol, U., Alacacioglu, A., Saray, S., Ozdemir, O., & Oktay Tarhan, M. (2021). Low dose (d1-5/7) oral etoposide regimen in intensively treated platinum-resistant epithelial ovarian cancer: The İzmir oncology group (IZOG) study . Annals of Medical Research | en_US |
| dc.identifier.uri | https://hdl.handle.net/11616/54748 | |
| dc.language.iso | en | en_US |
| dc.relation.ispartof | Annals of Medical Research | en_US |
| dc.rights | info:eu-repo/semantics/openAccess | en_US |
| dc.title | Low dose (d1-5/7) oral etoposide regimen in intensively treated platinum-resistant epithelial ovarian cancer: The İzmir oncology group (IZOG) study | en_US |
| dc.type | Article | en_US |
